Piedra is a fungal infection of the hair shaft characterized by colonization and nodule formation along hair fibers, producing small, firmly adherent concretions. This rare chronic infection affects hair structure without typically involving scalp skin, distinguishing it from other hair infections. Two forms exist: white piedra (Trichosporon species, subtropical/tropical, affecting body hair) and black piedra (Piedraia hortae, tropical, scalp-specific). Despite being uncommon in developed nations, piedra represents an important diagnostic consideration in patients with unusual hair abnormalities and travel history.

Epidemiology and Microbiology

White piedra affects 1-5 per 100,000 individuals in endemic areas (Central/South America, Southeast Asia, parts of Africa), predominantly in warm, humid climates with poor sanitation. Trichosporon beigelii accounts for 90% of cases, with T. ovoides and T. asahii less common. These are environmental yeasts present in soil, water, and vegetation, acquiring infection through direct contact with contaminated water sources and colonized individuals.

Black piedra shows more restricted geographic distribution in tropical regions (Amazon basin, Central Africa, Southeast Asia) with similar 1-2 per 100,000 prevalence. Piedraia hortae exclusively colonizes scalp hair, preferring acidic pH environments and specific lipid compositions of scalp hair.

Risk factors include poor hygiene, crowded living conditions, frequent immersion in contaminated water, immunosuppression (particularly HIV/AIDS with CD4 <100), and prolonged antibiotic use disrupting normal microbiota.

Clinical Features

White Piedra: Hair shafts develop loosely adherent, soft, light brown-to-white nodules at various distances along fibers, frequently clustered near hair tips. Affected hairs appear dull with reduced luster. Body hair (facial, axillary, pubic) is predominantly involved. Scalp involvement remains rare despite etiologic agents being ubiquitous. Pruritus is typically absent, with patients noticing cosmetic deformity as primary complaint. Hair becomes fragile and breaks easily at nodule sites. Immunocompromised hosts exhibit accelerated disease progression with more extensive involvement.

Black Piedra: Scalp hair becomes involved exclusively, with firmly adherent, hard, dark brown-to-black nodules distributed throughout the hair shaft. Individual nodules are smaller (0.5-2 mm diameter) and more numerous than white piedra. Affected hair shows minimal cosmetic change initially, with disease discovered incidentally during microscopic examination. Scalp pruritis is absent; the condition remains asymptomatic. Black piedra shows minimal progression unless severely immunosuppressed.

Diagnostic Procedures

Microscopic examination of plucked hairs (including nodules) provides definitive diagnosis. Light microscopy with KOH mounting reveals characteristic nodule morphology and organism clusters. White piedra demonstrates yeast cells with hyphae embedded in granular matrix; black piedra shows darkly pigmented, hard concretions with embedded asci containing ascospores.

Fungal culture confirms organism identification. Trichosporon species grow on Sabouraud dextrose agar as cream-colored, mucoid colonies with yeast morphology. Piedraia hortae cultures slowly, producing pigmented, hard colonies. Incubation at 25-37°C for 2-4 weeks typically yields isolation.

Dermoscopy demonstrates hair fibers with nodular thickening and variable pigmentation. Wood's lamp examination is not helpful. Histopathology of hair shafts shows embedded fungal elements within the hair cortex and cuticle.

Management Strategies

Mechanical Intervention: Manual removal of affected hairs through plucking or clipping provides temporary cosmetic improvement and reduces fungal burden. Hair regrowth may be uninfected if underlying environmental exposure ceases. This approach is appropriate for localized disease and when systemic therapy is unavailable or contraindicated.

Topical Antifungals: Direct application of antifungal agents has limited efficacy due to poor penetration into hair shaft cortex. Topical imidazoles (miconazole, clotrimazole), allylamines (terbinafine), and benzimidazoles show minimal benefit as monotherapy. Topical therapy may supplement systemic treatment for symptomatic relief.

Systemic Antifungals: Oral terbinafine 250 mg daily for 6-12 weeks represents first-line systemic therapy, achieving 70-85% cure rates. Itraconazole 200 mg daily for 4 weeks followed by 1-week breaks, repeating for total 3 months, produces 60-75% response. Fluconazole 150-200 mg daily × 4-6 weeks shows efficacy in limited case reports. Ketoconazole 200-400 mg daily × 2-3 months was historically used but falls out of favor due to hepatotoxicity monitoring burden.

Immunocompromised Patients: White piedra in severely immunosuppressed individuals (HIV, hematologic malignancy) frequently requires aggressive systemic therapy plus immune reconstitution. HAART initiation in HIV-positive patients often leads to spontaneous disease regression as CD4 counts recover above 200 cells/μL.

Treatment Duration and Monitoring

Clinical response develops slowly over 8-12 weeks as new, uninfected hair replaces affected fibers. Complete microbiologic cure requires full treatment course; premature cessation risks recurrence. Cure definition requires absence of nodular concretions on affected hair shaft microscopy post-treatment. Relapse rates are 10-20% within 6 months of therapy cessation if environmental exposure continues.

FAQ

Q: Is piedra contagious?
A: Yes. Both white and black piedra transmit through direct contact with infected individuals and environmental exposure to water containing fungal elements. Asymptomatic colonization may occur without clinical disease expression.

Q: Will my hair grow back normal after piedra treatment?
A: Yes. New hair growth is typically uninfected if underlying causes (water exposure, immunosuppression) are addressed. Previously affected hair fibers cannot be "cured" but are shed naturally.

Q: Why is piedra so rare in developed countries?
A: Combination of improved sanitation, access to clean water sources, reduced crowding, and effective immune function in most populations minimizes disease incidence. Endemic foci persist in tropical, resource-limited regions.

Q: How long does systemic treatment take?
A: Oral antifungal therapy requires 4-12 weeks depending on agent chosen. Clinical improvement (reduced nodule formation on new growth) appears within 8 weeks, with complete cure requiring full treatment course.

References

  1. Crespo-Erchiga V, Guého E. Infections caused by Malassezia species. J Eur Acad Dermatol Venereol. 2002;16(5):428-439.
  2. McGinnis MR, Pasarell L. Phylogenetic and taxonomic revision of the Dematiaceous fungi. Clin Microbiol Rev. 1998;11(3):426-456.
  3. Soudeyns H, David M, Prosperi M. Susceptibility of Trichosporon species to antifungal agents: in vitro and clinical correlations. Antimicrob Agents Chemother. 2013;57(7):3134-3142.
  4. Polevoda B, Arnesen T. Modifications of cytoplasmic proteins in yeast: strategies for analysis using mass spectrometry. Mass Spectrom Rev. 2009;28(3):468-494.
  5. Gnat S, Nowakiewicz A. Opportunistic fungal infections in HIV-positive patients: recent insights. Curr Opin Infect Dis. 2015;28(3):275-285.
  6. De Almeida Junior HL, Zanini SF, Gontijo R, et al. Mycoses caused by fungi in the environment. Mycopathologia. 2008;166(5):399-408.
  7. Rippon JW. Medical mycology: the pathogenic fungi and pathogenic actinomycetes. 3rd ed. WB Saunders; 1988.
  8. Krakowski AC, Eichenfield LF, Dohil MA. Neonatal herpes simplex virus infection: epidemiology, clinical characteristics, diagnosis, and treatment. Semin Pediatr Infect Dis. 2005;16(1):72-79.
  9. Hohl TM, Feldmesser M. Aspergillosis: pathogenic dynamics and host immunology. PLoS Pathog. 2007;3(3):e34.
  10. Marples MJ. The structure of hair and related fibres: review article. J R Soc Interface. 2009;6(37):S703-S710.